600% Kurspotential YM Biosciences 911799
| eröffnet am: | 14.03.06 11:16 von: | qwertz |
| neuester Beitrag: | 19.02.13 20:54 von: | der Eibsche |
| Anzahl Beiträge: | 694 | |
| Leser gesamt: | 151087 | |
| davon Heute: | 22 | |
bewertet mit 10 Sternen |
||
|
|
||
12.05.06 12:56
#76
joeflai
Und wenn nach der Meldung vom 10.05.
es noch Zweifler gibt, na dann versteh ich überhaupt nichts mehr!? Sollen se doch ihr Geld lieber bei Evotec, Mologen oder sonst wo reinstecken, selber schuld sag ich nur! Hier die Meldung,
- U.S. based Eximias provides YM with seasoned oncology management team and US $29 million -
MISSISSAUGA, Canada – May 9, 2006 - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA) today announced it has completed the acquisition of Eximias Pharmaceutical Corporation (Berwyn, Pennsylvania), a privately-held pharmaceutical company engaged in the acquisition, development and commercialization of products for the treatment of cancer and cancer-related disorders.
As a result of the transaction, YM gains more than US $29 million in cash and a seasoned oncology management team. Eximias will become a wholly-owned subsidiary of YM named YM BioSciences USA and will serve as the Company’s base of operations in the United States. Ms. Gail Schulze, President and CEO of Eximias, will become President of YM BioSciences and CEO of the US subsidiary.
“This transaction expands YM capabilities for the development and commercialization of its products currently in clinical development and establishes a presence for YM in the USA, particularly within the oncology and financial communities. In addition, with the closing of this transaction, YM’s working capital will exceed US $75 million, the most robust balance sheet in our Company’s history,” said David Allan, Chairman and CEO of YM BioSciences. “This will ensure YM is well positioned for the prospect of the clinical and regulatory success of tesmilifene without necessarily having to rely solely on a partner for its commercialization.”
Upon closing of the transaction YM BioSciences issued to the Eximias shareholders common shares priced at approximately US $5.75 in consideration for their shares and the accompanying working capital of approximately $29 million in Eximias. In addition YM BioSciences issued to the Eximias shareholders approximately 540,000 shares in recognition of the value of the organization. YM's common shares were issued at the volume weighted average price for the five-day period prior to the closing of the transaction.
“Eximias has substantial synergies with YM BioSciences. Our combined expertise and resources will significantly augment YM’s ability to execute additional clinical programs and to move its products into commercialization,” said Gail Schulze, President and CEO of Eximias. “The regulatory, commercialization and marketing experience within Eximias is extensive. Our team members have contributed to the successful development, approval or marketing of more than twenty marketed pharmaceutical products.”
Since its inception in 1998, Eximias has been supported by leading venture capital firms including New Enterprise Associates, Cross Atlantic Partners, Quaker BioVentures, OrbiMed Advisors, Caisse de Depot et Placements, VantagePoint Venture Partners and the Ontario Teachers’ Pension Plan.
Changes to YM’s Board of Directors and Management Team
The current management team of YM BioSciences will remain in place and will expand to include senior members of the Eximias management team who bring capabilities in clinical, regulatory, marketing, manufacturing and corporate development. Mr. David Allan will continue as Chairman and CEO of YM BioSciences and several appointments will be made to YM’s Board of Directors and management team, including:
Dr. James Barrett, currently a member of the Eximias Board of Directors, will join YM’s Board of Directors. Dr. Barrett is a General Partner at New Enterprise Associates, a leading venture capital firm, where he specializes in biotechnology and other healthcare investments. Dr. Barrett is a director on the boards of GlycoMimetics, Inc., Inhibitex, Inc., Iomai Corporation, MedImmune, Inc.,Peptimmune, Pharmion, Inc. and Targacept, Inc.
Ms. Gail Schulze, currently President and CEO of Eximias, will become President of YM BioSciences and CEO of YM BioSciences USA and will join YM's Board of Directors. Ms. Schulze has more than 25 years of pharmaceutical industry experience. Prior to joining Eximias, she was Chief Operating Officer of Aventis Behring, one of the world's leading pharmaceutical companies. She joined Aventis Behring as Senior Executive Vice President and Chief Marketing Officer in 1997 and became COO in 2001. Ms. Schulze received a BS in Psychobiology from the University of California, was an NIH Fellow in Neurophysiology at the University of Wisconsin and received an MBA from Stanford’s Graduate School of Business.
Dr. Lisa DeLuca will serve as Vice-President of Regulatory Affairs. Dr. DeLuca has more than 15 years of experience in the pharmaceutical industry, including her role as Director of Regulatory Affairs at AstraZeneca where she was responsible for the regulatory launch of IRESSA®. She has also held regulatory positions at Centocor and Wyeth and drug discovery positions at SmithKline Beecham (now GlaxoSmithKline) and The Upjohn Company (now Pfizer, Inc.). Dr. DeLuca received a PhD in biochemistry from the University of Toledo.
Mr. John Bennett will serve as Vice-President of Corporate Development. Mr. Bennett has more than 19 years of business development corporate finance experience in the pharmaceutical industry. Prior to Eximias, he served as Senior Vice President, Business Development at Aventis Behring and held a similar position at Rhone-Poulenc Rorer. Mr. Bennett is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from St. Joseph's University.
Mr. Scott Jackson will serve as Vice-President of Marketing. Mr. Jackson has more than 17 years of marketing and sales experience in the pharmaceutical and biopharmaceutical industries. Mr. Jackson was Senior Director, Oncology and Infectious Diseases at Centocor (Johnson and Johnson) and held commercial positions of increasing responsibility at ImClone Systems Incorporated, SmithKline Beecham and Eli Lilly & Co. Mr. Jackson holds a BS in Pharmacy from the Philadelphia College of Pharmacy and Science and an MBA from the University of Notre Dame.
Mr. Gary Floyd will serve as Vice-President of Operations. Mr. Floyd is a seasoned executive with an extensive background in the global pharmaceutical industry. He served as President of Pharmavene LLC, a pharmaceutical consulting firm. Prior to this, he was Senior Vice President, Worldwide Logistics and Procurement at Aventis Behring where he was responsible for Supply Chain Management of the company's global business. He also held senior positions in manufacturing, information systems, and sales and marketing at Aventis Behring and its predecessor companies.
Mr. James Updike will serve as Vice-President and General Manager, DELEX Therapeutics, reporting to Diana Pliura, CEO of DELEX. Mr. Updike brings over 17 years experience in the areas of business development, sales and marketing. Prior to Eximias, Mr. Updike was a Senior Director of Global Business Development for Wyeth Pharmaceuticals and held positions with R.P. Scherer Corporation, Hoffman La Roche and G.D. Searle Company. Mr. Updike's undergraduate degree is a Bachelor of Science from the University of Richmond and an MBA from The American University.
The YM common shares to be offered to Eximias stockholders pursuant to the transactions have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the United States in the absence of registration or an applicable exemption from the registration requirements of the Act.
Conference Call Notice
YM BioSciences will be holding a conference call for Analysts and Portfolio Managers to discuss the merger agreement on Wednesday, May 10, 2006 from 8:00am EST. To participate in the conference call, dial 1-800-218-0204. The conference call will also be audio cast live and archived for 90 days at www.ymbiosciences.com.
About YM BioSciences
YM BioSciences Inc. is a cancer product development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a 700-patient pivotal Phase III trial in metastatic and recurrent breast cancer. Published results from tesmilifene’s first Phase III trial in the same indication demonstrated a substantial increase in survival for women treated with the combination of tesmilifene and chemotherapy compared to chemotherapy alone, demonstrating that tesmilifene significantly enhanced the therapeutic effect of chemotherapy.
In addition to tesmilifene, YM is developing nimotuzumab, a humanized monoclonal antibody targeting the EGF receptor that has shown activity in a number of tumor types and which has demonstrated a superior side-effect profile compared to similar agents. The Company is also developing AeroLEF™, a unique inhalation delivered formulation of the established drug, fentanyl, to treat acute pain including cancer pain. This product has completed a Phase IIa trial with positive results and a randomized Phase IIb pain trial has been initiated. YM also has an anti-GnRH anti-cancer vaccine, Norelin™, for which Phase II data have been released and a broad portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells.
- U.S. based Eximias provides YM with seasoned oncology management team and US $29 million -
MISSISSAUGA, Canada – May 9, 2006 - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA) today announced it has completed the acquisition of Eximias Pharmaceutical Corporation (Berwyn, Pennsylvania), a privately-held pharmaceutical company engaged in the acquisition, development and commercialization of products for the treatment of cancer and cancer-related disorders.
As a result of the transaction, YM gains more than US $29 million in cash and a seasoned oncology management team. Eximias will become a wholly-owned subsidiary of YM named YM BioSciences USA and will serve as the Company’s base of operations in the United States. Ms. Gail Schulze, President and CEO of Eximias, will become President of YM BioSciences and CEO of the US subsidiary.
“This transaction expands YM capabilities for the development and commercialization of its products currently in clinical development and establishes a presence for YM in the USA, particularly within the oncology and financial communities. In addition, with the closing of this transaction, YM’s working capital will exceed US $75 million, the most robust balance sheet in our Company’s history,” said David Allan, Chairman and CEO of YM BioSciences. “This will ensure YM is well positioned for the prospect of the clinical and regulatory success of tesmilifene without necessarily having to rely solely on a partner for its commercialization.”
Upon closing of the transaction YM BioSciences issued to the Eximias shareholders common shares priced at approximately US $5.75 in consideration for their shares and the accompanying working capital of approximately $29 million in Eximias. In addition YM BioSciences issued to the Eximias shareholders approximately 540,000 shares in recognition of the value of the organization. YM's common shares were issued at the volume weighted average price for the five-day period prior to the closing of the transaction.
“Eximias has substantial synergies with YM BioSciences. Our combined expertise and resources will significantly augment YM’s ability to execute additional clinical programs and to move its products into commercialization,” said Gail Schulze, President and CEO of Eximias. “The regulatory, commercialization and marketing experience within Eximias is extensive. Our team members have contributed to the successful development, approval or marketing of more than twenty marketed pharmaceutical products.”
Since its inception in 1998, Eximias has been supported by leading venture capital firms including New Enterprise Associates, Cross Atlantic Partners, Quaker BioVentures, OrbiMed Advisors, Caisse de Depot et Placements, VantagePoint Venture Partners and the Ontario Teachers’ Pension Plan.
Changes to YM’s Board of Directors and Management Team
The current management team of YM BioSciences will remain in place and will expand to include senior members of the Eximias management team who bring capabilities in clinical, regulatory, marketing, manufacturing and corporate development. Mr. David Allan will continue as Chairman and CEO of YM BioSciences and several appointments will be made to YM’s Board of Directors and management team, including:
Dr. James Barrett, currently a member of the Eximias Board of Directors, will join YM’s Board of Directors. Dr. Barrett is a General Partner at New Enterprise Associates, a leading venture capital firm, where he specializes in biotechnology and other healthcare investments. Dr. Barrett is a director on the boards of GlycoMimetics, Inc., Inhibitex, Inc., Iomai Corporation, MedImmune, Inc.,Peptimmune, Pharmion, Inc. and Targacept, Inc.
Ms. Gail Schulze, currently President and CEO of Eximias, will become President of YM BioSciences and CEO of YM BioSciences USA and will join YM's Board of Directors. Ms. Schulze has more than 25 years of pharmaceutical industry experience. Prior to joining Eximias, she was Chief Operating Officer of Aventis Behring, one of the world's leading pharmaceutical companies. She joined Aventis Behring as Senior Executive Vice President and Chief Marketing Officer in 1997 and became COO in 2001. Ms. Schulze received a BS in Psychobiology from the University of California, was an NIH Fellow in Neurophysiology at the University of Wisconsin and received an MBA from Stanford’s Graduate School of Business.
Dr. Lisa DeLuca will serve as Vice-President of Regulatory Affairs. Dr. DeLuca has more than 15 years of experience in the pharmaceutical industry, including her role as Director of Regulatory Affairs at AstraZeneca where she was responsible for the regulatory launch of IRESSA®. She has also held regulatory positions at Centocor and Wyeth and drug discovery positions at SmithKline Beecham (now GlaxoSmithKline) and The Upjohn Company (now Pfizer, Inc.). Dr. DeLuca received a PhD in biochemistry from the University of Toledo.
Mr. John Bennett will serve as Vice-President of Corporate Development. Mr. Bennett has more than 19 years of business development corporate finance experience in the pharmaceutical industry. Prior to Eximias, he served as Senior Vice President, Business Development at Aventis Behring and held a similar position at Rhone-Poulenc Rorer. Mr. Bennett is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from St. Joseph's University.
Mr. Scott Jackson will serve as Vice-President of Marketing. Mr. Jackson has more than 17 years of marketing and sales experience in the pharmaceutical and biopharmaceutical industries. Mr. Jackson was Senior Director, Oncology and Infectious Diseases at Centocor (Johnson and Johnson) and held commercial positions of increasing responsibility at ImClone Systems Incorporated, SmithKline Beecham and Eli Lilly & Co. Mr. Jackson holds a BS in Pharmacy from the Philadelphia College of Pharmacy and Science and an MBA from the University of Notre Dame.
Mr. Gary Floyd will serve as Vice-President of Operations. Mr. Floyd is a seasoned executive with an extensive background in the global pharmaceutical industry. He served as President of Pharmavene LLC, a pharmaceutical consulting firm. Prior to this, he was Senior Vice President, Worldwide Logistics and Procurement at Aventis Behring where he was responsible for Supply Chain Management of the company's global business. He also held senior positions in manufacturing, information systems, and sales and marketing at Aventis Behring and its predecessor companies.
Mr. James Updike will serve as Vice-President and General Manager, DELEX Therapeutics, reporting to Diana Pliura, CEO of DELEX. Mr. Updike brings over 17 years experience in the areas of business development, sales and marketing. Prior to Eximias, Mr. Updike was a Senior Director of Global Business Development for Wyeth Pharmaceuticals and held positions with R.P. Scherer Corporation, Hoffman La Roche and G.D. Searle Company. Mr. Updike's undergraduate degree is a Bachelor of Science from the University of Richmond and an MBA from The American University.
The YM common shares to be offered to Eximias stockholders pursuant to the transactions have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the United States in the absence of registration or an applicable exemption from the registration requirements of the Act.
Conference Call Notice
YM BioSciences will be holding a conference call for Analysts and Portfolio Managers to discuss the merger agreement on Wednesday, May 10, 2006 from 8:00am EST. To participate in the conference call, dial 1-800-218-0204. The conference call will also be audio cast live and archived for 90 days at www.ymbiosciences.com.
About YM BioSciences
YM BioSciences Inc. is a cancer product development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a 700-patient pivotal Phase III trial in metastatic and recurrent breast cancer. Published results from tesmilifene’s first Phase III trial in the same indication demonstrated a substantial increase in survival for women treated with the combination of tesmilifene and chemotherapy compared to chemotherapy alone, demonstrating that tesmilifene significantly enhanced the therapeutic effect of chemotherapy.
In addition to tesmilifene, YM is developing nimotuzumab, a humanized monoclonal antibody targeting the EGF receptor that has shown activity in a number of tumor types and which has demonstrated a superior side-effect profile compared to similar agents. The Company is also developing AeroLEF™, a unique inhalation delivered formulation of the established drug, fentanyl, to treat acute pain including cancer pain. This product has completed a Phase IIa trial with positive results and a randomized Phase IIb pain trial has been initiated. YM also has an anti-GnRH anti-cancer vaccine, Norelin™, for which Phase II data have been released and a broad portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells.
12.05.06 14:49
#78
joeflai
Hier der erste Teil
Mississauga, Canada – May 9, 2006 - YM BioSciences Inc. kündigte heute an, dass sie den Erwerb von Eximias Pharmaceutical Corporation (Berwyn, Pennsylvanien) beendet hat, eine privat gehaltene Pharmagesellschaft engagierte im Erwerb, Entwicklung und Kommerzialisierung von Produkten für die Behandlung des Krebses und krebsgebundenes disorders.As ein Ergebnis des Geschäfts, YMs gewinnt mehr als US-$ 29 Millionen in bar und einer erfahrenen Onkologieverwaltung anschließen sich. Eximias wird eine hundertprozentige Tochtergesellschaft von YM mit dem Namen YM BioSciences USA und dient als die Basis von Operationen der Gesellschaft in den Vereinigten Staaten. Frau Gail Schulze, Präsident und Vorstandsvorsitzender von Eximias werden Präsident von YM BioSciences und Vorstandsvorsitzender von der US-Tochtergesellschaft. Dieses Geschäft dehnt YM Fähigkeiten zu der Entwicklung und Kommerzialisierung seiner Produkte gegenwärtig in klinischer Entwicklung aus und führt eine Gegenwart für YM in den USA besonders innerhalb der Onkologie und finanzieller Gemeinschaften ein.Außerdem übersteigt YMs aktives Kapital mit der Schließung von diesem Geschäft US-$ 75 Millionen, am meisten robuste Bilanz in der Geschichte unserer Gesellschaft "sagte David Allan, Vorsitzenden und Vorstandsvorsitzenden über YM BioSciences. Dies stellt sicher, dass YM gut für die Aussicht auf den klinischen und regulierenden Erfolg von tesmilifene platziert wird, ohne sich unbedingt einzig auf einen Partner für sein commercialization. verlassen zu müssen" Bei Schließung vom Geschäft, das YM BioSciences an die Eximias Aktionäre ausgab, zeichneten Stammaktien an ungefähr aus US-$ 5,75 in Überlegung für ihre Aktien und dem begleitenden aktiven Kapital von ungefähr $ 29 Millionen in Eximias. Außerdem gab YM BioSciences an die Eximias Aktionäre aus etwa 540.000 Aktien in Anerkennung vom Wert der Organisation. YMs Stammaktien wurden ausgestellt an das Volumen beschwerte für die fünftägige Periode Durchschnittspreis vor der Schließung vom Geschäft."Eximias hat wesentliche Synergien mit YM BioSciences. Unsere gemeinsame Sachkenntnis und unsere Ressourcen erweitern bedeutend YMs Fähigkeit, zusätzliche klinische Programme auszuführen und ihre Produkte in Kommerzialisierung zu bewegen, "sagte Gail Schulze, Präsidenten und Vorstandsvorsitzenden über Eximias. Die Regulierenden, Kommerzialisierungs- und Marketingerfahrung innerhalb Eximias ist weit reichend. Unsere Teammitglieder haben zu der erfolgreichen Entwicklung, Einverständnis oder Marketing des mehr als zwanzig vermarkteten Pharmakons products. beigetragen" Seit ihrem Beginn im Jahr 1998 ist Eximias durch Führen von Risikokapitalfirmen einschließlich neuer Unternehmenskollegen, Kreuzatlantischer Partner, Quäkers BioVentures, OrbiMed Berater, Caisse DE Depots, das et Platzierungen, VantagePoint Unterfangen sich zusammenschließen, und des Rentenplans der Ontario Lehrer unterstützt worden.
12.05.06 16:04
#79
der Eibsche
Merci
für den 1. Teil. Klingt doch ganz vielversprechend und nun ist YM auch in den USA live vor Ort. Diese Tatsache wird sich in dem Aktienkurs mit Sicherheit positiv bemerkbar machen. Immerhin sind die USA der wichtigste Markt für den Gesundheitssektor.
13.05.06 14:44
#80
der Eibsche
Quartalsbericht
Was kann man daraus schliessen? :
YM Biosciences 3Q Loss Widens
Friday May 12, 5:57 pm ET
YM Biosciences Posts Bigger 3Q Loss As Expenses Rise
NEW YORK (AP) -- YM BioSciences Inc., a developer of anticancer drugs, said Friday fiscal third quarter loss widened by 35 percent as the company ramped up spending on drug development.
Ontario-based YM lost 5.8 million Canadian dollars ($5.3 million), or 13 cents a share, compared with 4.3 million Canadian dollars ($3.9 million), or 12 cents a share, during the same period a year ago. Revenue more than tripled during the quarter hitting 685,000 Canadian dollars ($621,000) compared with 203,000 Canadian dollars ($184,000) a year prior, due to out-licensing agreements and interest.
ADVERTISEMENT
But expenses increased by 46 percent hitting 6.6 million Canadian dollars ($5.9 million) compared with 4.5 million Canadian dollars ($4.1 million) a year ago.
The company is juggling several clinical trials for drugs focusing on cancer treatment. Tesmilifene, for example, is currently in phase three clinical trials, being tested for its effectiveness on treating breast cancer.
Shares of YM BioSciences closed down 18 cents, or 3 percent, to $5.40 on the American Stock Exchange.
YM Biosciences 3Q Loss Widens
Friday May 12, 5:57 pm ET
YM Biosciences Posts Bigger 3Q Loss As Expenses Rise
NEW YORK (AP) -- YM BioSciences Inc., a developer of anticancer drugs, said Friday fiscal third quarter loss widened by 35 percent as the company ramped up spending on drug development.
Ontario-based YM lost 5.8 million Canadian dollars ($5.3 million), or 13 cents a share, compared with 4.3 million Canadian dollars ($3.9 million), or 12 cents a share, during the same period a year ago. Revenue more than tripled during the quarter hitting 685,000 Canadian dollars ($621,000) compared with 203,000 Canadian dollars ($184,000) a year prior, due to out-licensing agreements and interest.
ADVERTISEMENT
But expenses increased by 46 percent hitting 6.6 million Canadian dollars ($5.9 million) compared with 4.5 million Canadian dollars ($4.1 million) a year ago.
The company is juggling several clinical trials for drugs focusing on cancer treatment. Tesmilifene, for example, is currently in phase three clinical trials, being tested for its effectiveness on treating breast cancer.
Shares of YM BioSciences closed down 18 cents, or 3 percent, to $5.40 on the American Stock Exchange.
13.05.06 16:32
#81
MöchtegernBroker
würde ich als neutral bewerten
is ein Pharmaunternehmen -> Investitionen sind da an der Tagesordnung
und die Erlöse aus der Forschung kommen ja auch irgendwann ;-)
greetz und schönes WE
und die Erlöse aus der Forschung kommen ja auch irgendwann ;-)
greetz und schönes WE
16.05.06 13:25
#82
lucrum
Unter 4,00€
Mit meinem Kurs unter 4,00€ habe ich ja nun leider doch recht gehabt!
16.05.06 16:48
#84
joeflai
Hier mal ein paar Ausschnitte übersetzt
Gesamtaufwendungen für das Viertel, das 31. März 2006 beendet wurde, waren $6.558.668 verglichen bis $4.483.146 während der gleichen Periode letztes Jahr. Gesamtaufwendungen für die ersten neun Monate des 2006 steuerlichen Jahres waren $18.827.093 verglichen bis $10.443.903 für die ersten neun Monate der entsprechenden Periode letztes Jahr.
Allgemeine und Verwaltungskosten während des dritten Trimesters waren $1.876.575 und für die ersten neun Monate waren $4.558.347 verglichen bis $1.486.357 und $4.003.648 beziehungsweise während der gleichen Perioden im vorherigen Jahr. Unkosten Entwicklung und Produkt-während des dritten Trimesters waren $4.682.093 und für die ersten neun Monate genehmigten $14.268.746 verglichen bis $2.996.789 und $6.440.255 beziehungsweise während der gleichen Perioden im vorherigen Jahr. Aufwendung Zunahmen waren hauptsächlich zur schnellen Weiterentwicklung des tesmilifene Phase III klinischen Versuches und zur Einbeziehung der Kosten passend, die mit der Entwicklung der AeroLEF™ Technologie verbunden sind.
Reinverlust während des dritten Trimesters war $5.772.479 und für das Jahr waren bis jetzt $17.232.617 verglichen bis $4.277.762 und $9.376.625 beziehungsweise während der gleichen Perioden letztes Jahr.
Am 31. März 2006 hatte die Firma Bargeld und kurzfristige die Ablagerungs-, die $63.407.634 zusammenzählen und fällige kurzfristige Verbindlichkeiten von $3.686.028 verglichen bis $30.568.845 und $3.825.615 beziehungsweise bei 30. Juni 2005.
Allgemeine und Verwaltungskosten während des dritten Trimesters waren $1.876.575 und für die ersten neun Monate waren $4.558.347 verglichen bis $1.486.357 und $4.003.648 beziehungsweise während der gleichen Perioden im vorherigen Jahr. Unkosten Entwicklung und Produkt-während des dritten Trimesters waren $4.682.093 und für die ersten neun Monate genehmigten $14.268.746 verglichen bis $2.996.789 und $6.440.255 beziehungsweise während der gleichen Perioden im vorherigen Jahr. Aufwendung Zunahmen waren hauptsächlich zur schnellen Weiterentwicklung des tesmilifene Phase III klinischen Versuches und zur Einbeziehung der Kosten passend, die mit der Entwicklung der AeroLEF™ Technologie verbunden sind.
Reinverlust während des dritten Trimesters war $5.772.479 und für das Jahr waren bis jetzt $17.232.617 verglichen bis $4.277.762 und $9.376.625 beziehungsweise während der gleichen Perioden letztes Jahr.
Am 31. März 2006 hatte die Firma Bargeld und kurzfristige die Ablagerungs-, die $63.407.634 zusammenzählen und fällige kurzfristige Verbindlichkeiten von $3.686.028 verglichen bis $30.568.845 und $3.825.615 beziehungsweise bei 30. Juni 2005.
18.05.06 09:35
#86
joeflai
So ein Mist!
Hätte nicht gedacht das YM so böse trifft! Hatte bei 4 € nochmal nachgekauft! :-( Denke mal das wohl einige Stop losses ausgelöst wurden und generell sind die Börsen ja auf Talfahrt, also wollen wir mal hoffen das sie sich langsam wieder fängt!
25.05.06 22:56
#91
MöchtegernBroker
so ich hoff mal
dass wir den Tiefpunkt überstanden haben....hoffe der wieder leicht pos. Trend (durch die vielen Käufe) wird sich fortsetzten
26.05.06 00:03
#92
der Eibsche
3,50 - wer verkauft?
Hab bei 3,50 Euro noch `ne Kauforder hängen, gibts niemanden mehr der da noch was loswerden will?
26.05.06 09:22
#93
joeflai
@der Eibsche
Das häätste Dir vielleicht mal 2 Tage früher überlegen solln! :-) Ich denke, und hoffe, das das nun der Boden war und die Aktie sich langsam erholt!
26.05.06 09:27
#94
der Eibsche
@joeflai
...da war der Kurs bei 3,52..., es fehlten halt die 2 Cent...
26.05.06 09:31
#95
joeflai
Hättste mal
raufgesetzt, jetzt muste schon um die 8 % mehr hinblättern, im Augenblick. :-)
26.05.06 10:32
#96
MöchtegernBroker
denke
mal das es in den nächsten Tagen schön nach Norden geht, dann gehts meiner Meinung nach wieder mal 0,30€ nach unten, da ein Paar dann vll. schon Gewinne mitnehmen.
aber alles in allem gehts richtung Norden
greetzu und guten morgen@all
aber alles in allem gehts richtung Norden
greetzu und guten morgen@all
31.05.06 10:40
#100
der Eibsche
noch`n bisschen gen Süden...
mein Angebot steht noch: nehm `ne Fuhre bei 3,50...